Oligomerix, Inc

Oligomerix is a biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA. Oligomerix is headquartered at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Oligomerix has generated a significant amount of positive efficacy data across (7) animal studies, and the GLP toxicology studies have shown a good safety profile. We have secured non-dilutive funds from the U.S. Government to defray a substantial portion of the ongoing and planned clinical development programs, including a new grant approved in August 2025. We are also very active in engaging potential strategic partners, venture capital funds and pharmaceutical companies to invest in our company, in part led by our new Board Chairman William Caple, who joined the Board in July 2025.